Тромбоз, гемостаз и реология

Tromboz, Gemostaz I Reologiya
scientific and practical journal

ISSN 2078–1008 (Print); ISSN 2687-1483 (online)
2021, Original papers
2021

Biomarkers of vascular wall damage in patients with cerebrovascular diseases and type 2 diabetes mellitus: 616.8-005

Original papers
Published 2021-06-25
Mariya Bykovskaya
Research Center of Neurology; 80 Volokolamskoye Shosse, 125367 Moscow, Russia
ФГБУН «Научный центр неврологии»; Россия, 125367 Москва, Волоколамское шоссе, 80
Anton Raskurazhev
Research Center of Neurology; 80 Volokolamskoye Shosse, 125367 Moscow, Russia
ФГБУН «Научный центр неврологии»; Россия, 125367 Москва, Волоколамское шоссе, 80
Alla Shabalina
Research Center of Neurology; 80 Volokolamskoye Shosse, 125367 Moscow, Russia
ФГБУН «Научный центр неврологии»; Россия, 125367 Москва, Волоколамское шоссе, 80
Ksenia Antonova
Research Center of Neurology; 80 Volokolamskoye Shosse, 125367 Moscow, Russia
ФГБУН «Научный центр неврологии»; Россия, 125367 Москва, Волоколамское шоссе, 80
Marine Tanashyan
Research Center of Neurology; 80 Volokolamskoye Shosse, 125367 Moscow, Russia
ФГБУН «Научный центр неврологии»; Россия, 125367 Москва, Волоколамское шоссе, 80

Keywords

cerebrovascular diseases
type 2 diabetes mellitus
nitric oxide
asymmetric dimethylarginine
  Full Text

Abstract

Summary. Background. Vascular complications of diabetes mellitus (DM) are one of the leading causes of increased mortality in patients of employable age. Hyperglycemia-induced oxidative stress and impaired antioxidant protection have been suggested to play a role in the pathological mechanism of vascular damage, in part due to the effects of nitric oxide (NO). Objectives: clari- fication of relationships in the systems of asymmetric dimethylarginine (ADMA) and NO in patients with cerebrovascular diseases (CVD) and type 2 diabetes (DM-2). Patients/Methods. We examined 72 CVD patients with stenosing lesions of the internal carotid artery outside the acute period: group 1 consisted of 39 patients (18 men and 21 women; 65 [58; 72] years old) with DM-2; group 2 consisted of 33 patients (15 men and 18 women; 66 [56; 74] years old) without DM-2. The control group consisted of 30 volunteers (16 men and 14 women; 62 [50; 66] years old) without manifestations of cerebral ischemia and carbohydrate metabolism disorders, with normal body mass index, non-smokers. A clinical examination, neuro- and angio-imaging study, a spectrum of biochemical blood tests, including the concentration of asymmetric dimethylarginine (ADMA) and indicators of NO system were carried out. Results. In group 1, the content of nitrate, nitrite and NO was 62.1 [56; 68] μmol/l, 48.5 [26; 52] μmol/l and 13.6 [9; 23] μmol/l, respec- tively, that significantly differed from the content of these parameters in group 2 — 58.3 [45; 64] μmol/l, 39.6 [26.0; 42.3] μmol/l and 18.7 [16.1; 24.7] μmol/l, respectively. Noted also a higher blood level of ADMA in patients with CVD combined with DM-2 — 0.42 [0.21; 0.53] mmol/l. Conclusions. A relationship was found between ADMA and NO levels in CVD patients with DM-2. This requires further studies of biomarkers of vascular wall damage to determine their place in the pathogenesis of ischemic cerebral compli- cations of DM-2.

  1. Piradov M.A., Maksimova M. Yu., Tanashyan M.M. Stroke: step by step instruction. Moscow: GEOTAR-Media, 2019. 272 pp. (In Russ.). 

  2. Tanashyan M.M., Lagoda O.V., Antonova K.V., Raskurazhev A.A. The main pathogenetic mechanisms of vascular cerebral pathol- ogy associated with atherosclerosis and metabolic syndrome: the search for correction approaches. Annaly klinicheskoj i eksperimental’noj nevrologii. 2016;10(2):5–10. (In Russ.). 

  3. Oqurtsova K., da Rocha Fernandes J.D., Huang Y. et al. IDF diabe- tes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50. DOI: 10.1016/j. diabres.2017.03.024. 

  4. Krzyzanowska K., Mittermayer F., Woltz M. et al. ADMA, car- diovascular disease and diabetes. Diabetes Res Clin Pract. 2008;82(Suppl 2):S122–6. DOI: 10.1016/j.diabres.2008.09.024. 

  5. Tessari P., Cecchet D., Artusi C. et al. Roles of insulin, age, and asymmetric dimethylarginine on nitric oxide synthesis in vivo. Diabetes. 2013;62(8):2699–708. DOI: 10.2337/db12–1127. 

  6. Samoilova Yu.G., Rotkank M.A., Zhukova N.G. et al. Variability of glycemia in patients with type 1 diabetes mellitus: the rela- tionship with cognitive dysfunction and the results of magnetic resonance imaging. Problemy endokrinologii. 2018;64(5):286–91. (In Russ.). DOI: 10.14341/probl9589. 

  7. Knapp M., Tu X., Wu R. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. Acta Pharmacol Sin. 2019;40(1):1–8. DOI: 10.1038/s41401–018–0042–6. 

  8. Watts G.F, Playford D.A. Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insu- lin dependent diabetes: a hypothesis. Atherosclerosis. 1998;141(1):17– 30. DOI: 10.1016/s0021–9150(98)00170–1. 

  9. Makimattila S., Liu M., Vakkilailnen J. et al. Impaired endothe- lium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care.1999;22(6):973– 81. DOI: 10.2337/diacare.22.6.973. 

  10. Tan K C., AiV.H., ChowW.S. et al. Influence of low density lipo- protein (LDL) subfraction profile and LDL oxidation on endothe- lium-dependent and independent vasodilation in patients with type 2 diabetes. J Clin Endocrinol Metab. 1999;84(9):3212–6. DOI: 10.1210/jcem.84.9.5959. 

  11. Skyrme-Jones R.A., O’Brien R.C., Luo M. et al. Endothelial vaso- dilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in type 1 dia- betes. J AmColl Cardiol. 2000;35(2):292–9. DOI: 10.1016/s0735– 1097(99)00547–1. 

  12. Forbes J.M., Cooper M.E. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–88. DOI: 10.1152/physrev.00045.2011. 

  13. Brownlee M. Biochemistry and molecular cell biology of dia- 
betic complications. Nature. 2001;414(6865):813–20. DOI: 
1038/414813a. 

  14. Forrester S.J., Kikuchi D.S, Hernandes M.S. et al. Reactive oxy- 
gen species in metabolic and inflammatory signaling. Circ Res. 
2018;122(6):877–902. DOI: 10.1161/CIRCRESAHA.117.311401. 

  15. Clealand S.J., Petrie J.R., Small M. et al. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension. 2000;35(1 Pt 2):507–11. DOI: 10.1161/01.hyp.35.1.507. 

  16. Zeng G., Nystrom F.H., Racichandran L.V. et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation. 2000;101(13):1539–45. DOI: 10.1161/01.cir.101.13.1539.
  17. Mangiacapra F., Conte M., Demartini C. et al. Relationship of asymmetric dimethylarginine (ADMA) with extent and functional severity of coronary atherosclerosis. Int J Cardiol. 2016;220:629– 33. DOI: 10.1016/j.ijcard.2016.06.254.
  18. Song Y., Qu X., Yu Y.et al. Relationship between plasma asymmet- rical dimethylarginine and coronary artery disease. Zhonghua Yi Xue Za Zhi. 2007;87(22):1527–30. [Article in Chinese].
  19. Lu T.-M., Ding Y.-A., Charng M.-J. et al. Asymmetrical dimethyl- arginine: a novel risk factor for coronary artery disease. Clin Car- diol. 2003;26(10):458–64. DOI: 10.1002/clc.4960261006.
  20. Eid H.M., Reims H., Arnesen H. et al. Decreased levels of asymmet- ric dimethylarginine during acute hyperinsulinemia. Metabolism. 2007;56(4):464–9. DOI: 10.1016/j.metabol.2006.11.003.
  21. Tahara N., Yamagishi S., Mizoguchi M. et al. Pioglitazone decreases asymmetric dimethylarginine levels in patients with impaired glu- cose tolerance or type 2 diabetes. Rejuvenation Res. 2013;16(5):344– 51. DOI: 10.1089/rej.2013.1434.
  22. Kruszelnicka O., Chyrchel B., Golay A. et al. Differential associa- tions of circulating asymmetric dimethylarginine and cell adhe- sion molecules with metformin use in patients with type 2 dia- betes mellitus and stable coronary artery disease. Amino Acids. 2015;47(9):1951–9. DOI: 10.1007/s00726–015–1976–3.
  23. Bestermann W.H. The ADMA-metformin hypothesis: linking the cardiovascular consequences of the metabolic syndrome and type 2 diabetes. Cardiorenal Med. 2011;1(4):211–9. DOI: 10.1159/000332382.
  24. Furuki K., Adachi H., Matsuoka H. et al. Plasma levels of asymmet- ric dimethylarginine (ADMA) are related to intima-media thick- ness of the carotid artery: an epidemiological study. Atherosclero- sis. 2007;191(1):206–10. DOI: 10.1016/j.atherosclerosis.2006.03.022.
  25. Gimbrone M.A., García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118(4):620– 36. DOI: 10.1161/CIRCRESAHA.115.306301.
  26. Kaur R., Kaur M., Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17(1):121. DOI: 10.1186/s12933–018–0763–3.
  27. Souilhol C., Serbanovic-Canic J., Fragiadaki M. et al. Endothe- lial responses to shear stress in atherosclerosis: a novel role for developmental genes. Nat Rev Cardiol. 2020;17(1):52–63. DOI: 10.1038/s41569–019–0239–5.
  28. Chertok V.M., Kocjuba A.E., Bespalova E.P. The role of nitric oxide in the reaction of blood vessels to laser irradiation. Bull Exp Biol Med. 2008;145(6):751–4. DOI: 10.1007/s10517–008–0186–3.
  29. Ali M Y., PingC.Y., MokY.Y. et al. Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? Br J Pharmacol. 2006;149(6):625–34. DOI: 10.1038/ sj.bjp.0706906.
  30. BooY.C., JoH.Flow-dependent regulation of endothelial nitric oxide synthase: role of protein kinases. Am J Physiol Cell Physiol. 2003;285(3): C499–508. DOI: 10.1152/ajpcell.00122.2003.
  31. Toda N., Ayajiki K., Okamura T. Cerebral blood flow regulation by nitric oxide: recent advances. Pharmacol Rev. 2009;61(1):62– 97. DOI: 10.1124/pr.108.000547.
  32. Walford G., Loscalzo J.Nitric oxide in vascular biology. J Thromb Haemost. 2003;1(10):2112–8. DOI: 10.1046/j.1538– 7836.2003.00345.x.
  33. Austin S.A., Katusic Z.S. Partial loss of endothelial nitric oxide leads to increased cerebrovascular beta amyloid. J Cereb Blood Flow Metab. 2020;40(2):392–403. DOI: 10.1177/0271678X18822474.
  34. Huang A., Yang Y.-M., Feher A. et al. Exacerbation of endothelial dysfunction during the progression of diabetes: role of oxidative stress. Am J Physiol Regul Integr Comp Physiol. 2012;302(6): R674– 81. DOI: 10.1152/ajpregu.00699.2011.
  35. Wang M., Sui J., Wang S., Wang X. Correlations of carotid intima-media thickness with endothelial function and athero- sclerosis degree in patients with type 2 diabetes mellitus. Clin Hemorheol Microcirc. 2019;72(4):431–9. DOI: 10.3233/CH-180486.
  36. Ifrim S., Vasilescu R. Early detection of atherosclerosis in type 2 diabetic patients by endothelial dysfunction and intima-media thickness. Rom J Intern Med. 2004;42(2):343–54.
  37. Liu X., Xu X., Shang R., Chen Y. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovas- cular diseases and heart failure in chronic kidney disease. Nitric Oxide. 2018;78:113–20. DOI: 10.1016/j.niox.2018.06.004.
  38. Rodionov R.N., Jarzebska N., Schneider A. et al. ADMA eleva- tion does not exacerbate development of diabetic nephrop- athy in mice with streptozotocin-induced diabetes mellitus. Atherosclerosis Supplements. 2019;40:100–5. DOI: 10.1016/j.ath- erosclerosissup.2019.08.040.
  39. Xia W., Shao Y., WangY. et al. Asymmetric dimethylarginine and carotid atherosclerosis in Type 2 diabetes mellitus. J Endocrinol Invest. 2012;35(9):824–7. DOI: 10.1007/BF03347101.
  40. Celik M., Cerrah S., Arabul M., Akalin A. Relation of asym- metric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabetic patients. J Diabetes Res. 2104;2014:139215. DOI: 10.1155/2014/139215.
  41. Konya H., Miuchi M., Satani K. et al. Asymmetric dimethylar-ginine, a biomarker of cardiovascular complications in diabetes mellitus. World J Exp Med. 2015;5(2):110–9. DOI: 10.5493/wjem. v5.i2.110.